Abramson Cancer Center

Hematological Malignancies (Blood Cancer) Program

Abramson Cancer Center hematologic malignancies’ clinicians and researchers have led the way nationally for years; both in the care of patients with hematologic malignancies (blood cancer) and in its research.

Today, there's more hope than ever for those who face a blood cancer diagnosis.

Penn’s program is one of the oldest and largest in the country. By putting our experience to work, we offer the best possible treatment outcomes.

Penn has one of the few Hematologic Malignancy (leukemia, lymphoma and myeloma) Research Programs in the country that is approved and funded by the National Cancer Institute. It is through this research program that Penn has made significant advances in improving bone marrow and stem cell transplants and the care of patients with blood cancer.

The knowledge gained through our research allows us to better care for those with blood cancers.

To learn about what sets us apart, visit:

• The Penn Difference
• Premier Research Program
• Team Approach/Multidisciplinary Care
• About our Physicians/Staff

Survivor Stories

Brian Trainor

It was on January 7^th that Penn law student Brian Trainor, a healthy and active 31 year old with no known symptoms had a sudden seizure. Brian was rushed to HUP, where he received a CT scan and MRI, which uncovered a 2.5 centimeter tumor on the left frontal lobe of his brain.